Free Trial

Pluxee (PLXFP NR/BBB+/NR) 3Q Results Recap

CONSUMER CYCLICALS

Earnings were Wednesday after the close (not morning, apologies). We thought results were going to be firm given the equity px action late on Tuesday (+5.8%) and results were in our eyes but apparently not for equities (-9% yesterday). Summary, which DG covered, was +17.9% organic growth (to €297m) and upgrade to FY24 guidance from +16-17% to +18%. Given YTD revenue has been +21.8% (at €889) it implies a slow down to HSD growth in Q4 - more on that below. All other guidance was unch including recurring EBITDA margin >35%. Medium-term targets were unch.

We attribute the equity px action (€4b market cap) to 1) implied slow-down in 4Q and unch EBITDA margin guidance despite headline lift and 2) potential nerves heading into French election and associated regulation uncertainty. On the former we'd note Pluxee is a growth stock trading at a 20x P/E vs. SXXP's 14x and is sensitive to changes in short-term expectations (even from HDD to MDD growth). On the 2nd point Pluxee does not disclose French exposure but Europe is 43% of revenue and Cobee acquisition is a step into the Spanish market. Larger Edenred's was at 15% of EBIT last year - it brings Q2 results (3m to June) on 23rd of July - watch for comments there too.

Keep reading...Show less
581 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.

Earnings were Wednesday after the close (not morning, apologies). We thought results were going to be firm given the equity px action late on Tuesday (+5.8%) and results were in our eyes but apparently not for equities (-9% yesterday). Summary, which DG covered, was +17.9% organic growth (to €297m) and upgrade to FY24 guidance from +16-17% to +18%. Given YTD revenue has been +21.8% (at €889) it implies a slow down to HSD growth in Q4 - more on that below. All other guidance was unch including recurring EBITDA margin >35%. Medium-term targets were unch.

We attribute the equity px action (€4b market cap) to 1) implied slow-down in 4Q and unch EBITDA margin guidance despite headline lift and 2) potential nerves heading into French election and associated regulation uncertainty. On the former we'd note Pluxee is a growth stock trading at a 20x P/E vs. SXXP's 14x and is sensitive to changes in short-term expectations (even from HDD to MDD growth). On the 2nd point Pluxee does not disclose French exposure but Europe is 43% of revenue and Cobee acquisition is a step into the Spanish market. Larger Edenred's was at 15% of EBIT last year - it brings Q2 results (3m to June) on 23rd of July - watch for comments there too.

Keep reading...Show less